Sign up to save your podcasts
Or
Share Discontinuing lenalidomide maintenance in MM; congenital neutropenia syndrome linked to COPZ1 mutations; low GVHD rates with ruxolitinib after allogeneic HCT
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Discontinuing lenalidomide maintenance in MM; congenital neutropenia syndrome linked to COPZ1 mutations; low GVHD rates with ruxolitinib after allogeneic HCT
In this week's episode, we'll learn about stopping myeloma maintenance therapy in the modern era. New research suggests that many patients in remission can discontinue lenalidomide, remaining treatment-free, without jeopardizing disease response. After that: a novel congenital neutropenia syndrome. Mutations in the COPZ1 gene impact myeloid differentiation and development of neutropenia. Researchers describe the mechanisms and propose a treatment strategy for restoring granulopoiesis. Finally, ruxolitinib maintenance therapy after allogeneic transplant. In a phase 2 study, this treatment strategy was associated with low rates of chronic graft-versus-host disease. Investigators say the use of JAK inhibitors in this context warrants further study.
Featured Articles:
- Sustained bone marrow and imaging MRD negativity for 3 years drives discontinuation of maintenance post-ASCT in myeloma
- A new severe congenital neutropenia syndrome associated with autosomal recessive COPZ1 mutations
- Low rates of chronic graft-versus-host disease with ruxolitinib maintenance following allogeneic HCT
View all episodes
By American Society of Hematology
4.1
4848 ratings
In this week's episode, we'll learn about stopping myeloma maintenance therapy in the modern era. New research suggests that many patients in remission can discontinue lenalidomide, remaining treatment-free, without jeopardizing disease response. After that: a novel congenital neutropenia syndrome. Mutations in the COPZ1 gene impact myeloid differentiation and development of neutropenia. Researchers describe the mechanisms and propose a treatment strategy for restoring granulopoiesis. Finally, ruxolitinib maintenance therapy after allogeneic transplant. In a phase 2 study, this treatment strategy was associated with low rates of chronic graft-versus-host disease. Investigators say the use of JAK inhibitors in this context warrants further study.
Featured Articles:
- Sustained bone marrow and imaging MRD negativity for 3 years drives discontinuation of maintenance post-ASCT in myeloma
- A new severe congenital neutropenia syndrome associated with autosomal recessive COPZ1 mutations
- Low rates of chronic graft-versus-host disease with ruxolitinib maintenance following allogeneic HCT
More shows like Blood Podcast
View all
JAMA Editors' Summary
129 Listeners
Hematologic Oncology Update
72 Listeners
NEJM This Week
318 Listeners
The Hematologist
26 Listeners
JAMA Clinical Reviews
487 Listeners
Mayo Clinic Talks
272 Listeners
VJHemOnc Podcast
2 Listeners
Annals On Call Podcast
185 Listeners
The Curious Clinicians
362 Listeners
The BSH Guidelines Official Podcast
3 Listeners
EHA Unplugged
2 Listeners
WolverHeme Happy Hour
29 Listeners
Two Onc Docs
166 Listeners
Blood Cancer Talks
48 Listeners
HemeTalks: Conversations in Hematology Education
1 Listeners